Trial · NCT04998786
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of patients have very good partial response (VGPR) or better | approximate 18 months | Using IMWG criteria |
| Secondary | Number of adverse events | approximate 18 months | Number of adverse events defined by Common Terminology Criteria for Adverse Events (v5) |
| Secondary | Number of responses | 3 months | Partial Response (PR), Very Good Partial Response (VGPR), Complete Response (CR) and minor response (MR) will be evaluated according to IMWG |
| Secondary | Number of responses | 6 months | Partial Response (PR), Very Good Partial Response (VGPR), Complete Response (CR) and minor response (MR) will be evaluated according to IMWG |
| Secondary | Number of the death | approximate 18 months | is defined as the time in months from inclusion to the date of death due to any cause. Subject alive will be censored at the last known alive date. |
| Secondary | Number of progression | approximate 18 months | is defined as the time in months from inclusion to the date of disease progression or death due to any cause, using IMWG criteria |
| Secondary | Percentage of time to progression | approximative 18 months | is defined as the time in months from inclusion to the date of disease progression or death due to any cause, using IMWG criteria |
| Secondary | Percentage of duration of response | approximative 18 months | is defined as the time from the first response (PR or better) to the date of disease progression or death due to any cause |
| Secondary | Percentage of duration of therapy | approximative 18 months | is defined as the time from treatment initiation to the last dose of therapy |
| Secondary | Percentage of time to response | approximative 18 months | according IMWG |
| Secondary | Percentage of Overall Response Rate | approximative 18 months | according IMWG |
| Secondary | Percentage of value of biological prognostic factors | day 1 | prognostic factors as ISS stage, cytogenetic as del(17p), t(4;14), |
| Secondary | Percentage of frailty scores | day 1 | age, ECOG, comorbidity index |
| Secondary | Percentage of score of quality of life | approximative 18 months | To assess Quality of Life EQ5D and SF36 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04998786/registered